Lauxera Capital Partners invests in LUMICKS
LUMICKS, a leading, next generation life science tools company that develops highly innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, announced the completion of a $93 million Series D preferred share financing.
The funding round was led by new investors Farallon Capital Management and Lauxera Capital Partners, and included investments by Softbank Vision 2i, funds and accounts advised by T. Rowe Price Associates, Parian Global Management, Pura Vida Investments, and Irving Investors. The round was also backed by existing investor Gilde Healthcare and select members of the LUMICKS management team. A majority of the proceeds from the financing will be used to bolster growth initiatives including expansion of both research and development and commercial activities for the z-Movi® Cell Avidity Analyzer.
Koen van MiddelaarAssociate Attorney at law
Koen van Middelaar, attorney at law, is a member of the Corporate practice group in our Amsterdam office.
Before joining the Corporate practice group, Koen was a member of the Litigation & Risk Management practice group, where he gained experience in advising and litigating on commercial and corporate disputes.
Jet de Mol van OtterlooAssociate Attorney at law
Jet de Mol van Otterloo, associate, is a member of the Competition & Regulatory practice group in our Amsterdam office. She focuses on corporate law (mergers & acquisitions) in the healthcare sector.T: +31 20 578 5833 M: +31 6 52 00 59 69 E: firstname.lastname@example.org